Loading…
This event has ended. Visit the official site or create your own event on Sched.
This year, Partners in Digital Health, publishers of Blockchain in Healthcare Today and Teleheath and Medicine Today, presented a full day of concurrent tracks featuring  the foremost  innovators and savants in blockchain technology, telehealth, AI, and other novel technologies convened  at the Convege2Xcelerate  (#ConV2X),  healthcare modernization event,  to address the most compelling issues, growth opportunities, and financial implications for the industry.

Sector leadership  converged to share and challenge the integration of emerging technologies to accelerate building a new framework for the future of patient care, and modernization of a new health system.

Register now to receive your  podcast edition  alert from BHTY and TMT.

BHTY registration:  https://blockchainhealthcaretoday.com/index.php/journal/user/register
TMT registration: https://telehealthandmedicinetoday.com/index.php/journal/user/register

SPECIAL THANKS TO:
CONSENSYS HEALTHPLATINUM SPONSOR,  CONFERENCE AND BLOCKCHAIN TRACK
BOEHRINGER INGELHEIMBRONZE SPONSOR 

Sponsors:
BurstIQ  |  1800PR  |  Cadent Medical Communication  | HealthVerity  |  Izzy  |  Nonnatech

Media Partners:
Healthcare Informatics  |  Health Data Management  |  Pharmacy Podcast

and all our Friends...
https://convergetoaccelerate2018.sched.com/directory/sponsors

See you in 2019...!
avatar for Julia Saiz Shimosato

Julia Saiz Shimosato

Syneos Health
SVP
Julia has over 15 years of experience in the field of medical communications, education, and advertising.  She holds a doctoral degree in molecular genetics from the University of Salamanca (Spain) and spent 5 years as a postdoctoral research fellow, later associate, at Memorial Sloan Kettering Cancer Center, New York, NY, investigating the mechanisms of cell division control and their relationship to potential oncogenic processes.

Working with pharmaceutical, biotech clients, academic institutions, and professional societies, Julia has provided strategic solutions via publications, educational programs, and promotional campaigns, from the development of concepts and messaging, to final deliverables. Her expertise includes genetic diseases, rheumatology/immunology, cardiovascular and respiratory medicine, and oncology.

Julia has an extensive track record in publications, from conceptual multi-year planning, to successful execution of high-quality, high-science manuscripts or congress presentations (phase I-III clinical trials, as well as clinical biomarker discovery data sets). Among other brands, Julia led the multi-indication publication efforts for Erbitux (cetuximab) and Tarceva (erlotinib) when these products transitioned from widely-defined indications to biomarker-based clinical use. Julia has also worked developing promotional and medical strategies for major brands, such as Erbitux (cetuximab), Velcade (bortezomib), Empliciti (elotuzumab), Orkambi (lumacaftor/ivacaftor), Eliquis (apixaban) and Cimzia (certolizumab pegol), playing an instrumental role in developing positioning platforms and strategic messaging from inception to market research.

Recently, Julia has been supporting several major brands in the field of oncology/hematology, and immunology including multiple antibodies and large molecules, both for US and global teams. Julia acts as medical director, leading content development and management for publications and other scientific output.